Article
Author(s):
Bausch + Lomb has agreed to acquire the Blink product line for $106.5 million.
Bausch + Lomb Corp. announced an affiliate has purchased the Blink product line of eye and contact lens drops from Johnson & Johnson Vision.
According to the company, the acquisition is the latest example of the company’s commitment to increasing over-the-counter (OTC) consumer convenience in eye care.
Under the terms of the deal, Bausch + Lomb agreed to acquire the Blink product line for $106.5 million with cash on hand, according to a company news release.
“There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” John Ferris, executive vice president, Consumer, Bausch + Lomb, said in a news release. “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”
According to a 2022 Gallup Study, 57% of American adults report suffering from eye dryness, and of them, nearly half (48%) use OTC lubricant drops to obtain relief. The incidence is increasing, with a strong correlation between the amount of time spent on digital devices and reported dry eyes.1 In addition, contact lens discomfort and contact lens dryness impacts a third of the 45 million contact lens wearers in the United States.2,3,4
The Blink portfolio of eye drops consists of a variety of eye drops and contact lens rewetting drops that provide immediate and long-lasting symptom relief. The products that are part of the acquisition include the following:
First patient dosed at the Tokyo Medical Center by Belite Bio in Phase 2/3 DRAGON II clinical trial